Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04151563
Recruitment Status : Not yet recruiting
First Posted : November 5, 2019
Last Update Posted : February 17, 2020
Clovis Oncology, Inc.
Eli Lilly and Company
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : November 27, 2024
Estimated Study Completion Date : November 27, 2024